DESTINY-Breast04: practice-changing results for HER2-low breast cancer
Is HER2-low a distinct subtype of breast cancer?
HER2-Low Breast Cancer: DESTINY or Good Science?
Questions remaining in the field of HER2-low breast cancer
Remaining questions surrounding HER2-low breast cancer – how low can you go?
Remaining questions on the management of HER2-low breast cancer
The exciting new field of HER2-low breast cancer
Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate
Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review
Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm
Clinical outcomes in women with metastatic HER2-low breast cancer in the real world
Novel treatment options for HER2-low breast cancer
Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?
Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer
ADCs for the treatment of HER2-low breast cancer
Highlights in HER2-low breast cancer at SABCS 2022
Remaining questions regarding HER2-low breast cancer
HER2-low expression in breast cancer
HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review Conference
Biological behaviour of HER2-low BC is dependent on HR expression